explore -WSS

explore

author：Wikipedia 2025-10-01 17:20:20 - browse：4995

illustration of one blue dna strand — Adobe

The Food and Drug Administration is convening a meeting of outside experts on Tuesday to review exa-cel, a CRISPR-based treatment for sickle cell disease made by Vertex Pharmaceuticals and CRISPR Therapeutics.

Tuesday’s meeting is set up a bit differently than most FDA advisory panels. The agency has not raised any concerns about exa-cel’s efficacy or safety, and there will not be a typical vote at the end of the day on whether the data from exa-cel’s pivotal clinical trial support an approval as a treatment for sickle cell disease.

Instead, the FDA is seeking input about the methods used by Vertex and CRISPR Therapeutics to evaluate the risk of inadvertently making unwanted changes to patients’ DNA — so-called off-target editing — when exa-cel is administered.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Diversify hospital leadership teams to protect BIPOC patient health

WSS

Senate bill would ban some hospital facility fees

A clever new way to fix Medicaid and graduate medical education

Don't let 'shelved assets' gather dust. Make them into new lifesaving drugs

People with substance use disorder deserve online privacy

FDA approves potent Eli Lilly obesity drug, Zepbound

FDA weighs limits of animal data in assessing artificial wombs

hotspot

explore

focus

Apple is now the first public company to be valued at $3 trillion

The struggle to figure out which patients 'deserve' Wegovy

In Memoriam: Notable people who died in 2023

Neurocrine congenital adrenal hyperplasia trial succeeds

Guidelines to prevent youth baseball injuries need more muscle

Abortion clinic in Cancun will cater to Americans

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Covid’s new normal has set in amid another rise in cases

State Dept. review finds Biden bears some blame for Afghanistan failures

White House Covid adviser calls on docs to combat misinformation

entertainment

David Liu startup to focus on CRISPR delivery

Will General Catalyst be the first of many hospital takeovers?

Akili changes sales model for its ADHD video game treatment

Don't let 'shelved assets' gather dust. Make them into new lifesaving drugs

Why the drug industry's warnings on the IRA's impact fall short

MoonLake credibility takes another hit with mid

knowledge

focus

focus

knowledge